Bavarian Nordic partner files chikungunya vaccine for Brazil Anvisa approval

• Eurofarma filed a marketing authorization application with Brazil’s Anvisa for Bavarian Nordic’s CHIKV VLP chikungunya vaccine for ages 12 and older.
• The submission advances the partners’ January 2026 exclusive distribution deal for Brazil, with Eurofarma leading regulatory work, commercialization, distribution.
• The single-dose vaccine is already cleared in the US, EU, UK, Switzerland, Canada under the VIMKUNYA brand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130900OMX_____CNEWS_DA_GNW1001212510_da) on July 13, 2026, and is solely responsible for the information contained therein.